Our Speakers
The pharmaceutical industry drives innovation - Trends in the German healthcare market 2026 and beyond
Susanne van der Beck, Senior Director IQVIA Germany
Key success factors for pharmaceutical companies in Germany, and how BPI can support”
Germany is currently the 4th largest pharmaceutical market in the world, supported by a statutory healthcare system that provides services to over 80 million citizens.
The country offers rapid market access and reimbursement for innovative medicines, making it an attractive destination for pharmaceutical companies.
The BPI, with over 70 years of experience, is the only national association representing the ENTIRE pharmaceutical industry portfolio, encompassing around 230 member companies from large multinationals to SMEs and startups.
BPI provides members with valuable services, including analyses, information and OPERATIONAL SUPPORT FOR ITS MEMBERS on current topics, and facilitates discussions through over 50 working groups.
The organization plays a crucial role in advocating for industry interests with policymakers at various governmental levels.
Dr. med. Kai Joachimsen, MBA, Bundesverband der Pharmazeutischen Industrie e.V., CEO
Mastering a License Deal
Licensing agreements seem to be easy and straight forward. However there are traps to be considered. .Precise business planning is key, being the basis for the right rationale to calculate the license fees. What do we license in/out in the end? Does it give the anticipated scope to the licensee, does it still allow the licensor the freedom to operate?
Manfred Stadler, Partner, VINC advisory
AI in Pharma: a transformative Pilot in Market Access
This session will provide you with valuable insights into how AI can transform your operations today and prepare you for tomorrow’s challenges in critical fields like regulatory affairs and quality management.
You will also discover CLEVAIR-HTA, our advanced AI solution designed to support your market access needs while paving the way for broader integration tailored to the unique needs of small and medium-sized pharmaceutical companies.
Henry Jonckheere and Marc Czarka, Administrators MAEVH sas
Bio-Pharma CEO Survey and Report Future Optimism Score
VINC’s yearly Bio-Pharma CEO Report, that is being prepared in co-operation with EuropharmSMC, provides exclusive industry insights, which support top management in strategic decision-making as well as in identifying growth and investment opportunities. It provides insights on strategic topics from SMEs for SMEs in pharma and bio-pharma (incl. service providers) – a report that is unparalleled.
VINC will present the highlights of the Future Optimism Score 2025 and will also outline what will be new in the upcoming report.
Highlights of the report:
• Market Sentiment and Outlook: Industry insights and perspectives of European Bio-Pharma CEOs
• Investment Trends: Analysis of key investment priorities and financial outlooks
• Strategic Partnerships: Overview of collaboration strategies driving growth and innovation
New this year: For the first time, business leaders will be able to benchmark their personal data against industry peers.
Thomas Kern, Managing Director, VINC Healthcare Advisory and ISP HEALTHCARE